Biodegradable Copolymer Anti-Adhesion Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anti-adhesion medical devices often fail due to rapid degradation, macroscopic fracturing, tissue necrosis, and excessive fibrosis, leading to loss of barrier functionality and chronic inflammatory responses, which can result in adverse clinical outcomes such as scarring and impaired tissue healing.
Innovation Solution
A medical copolymer comprising biodegradable polylactic acid and polyethylene glycol linked via urethane or urea groups, which maintains planar integrity during degradation, reduces pH changes, and minimizes the formation of macroscopic fracturing and fibrosis, thereby preventing tissue adhesions and promoting biocompatible absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If rapidly absorbing implants comprised of polylactic acid are used, then absorption rate is improved, but tissue necrosis occurs due to hydronium ion release
Solution Approach 1:
The patent uses a composite polymeric composition combining polylactic acid with polyethylene glycol and polypropylene glycol in specific ratios (PLA:PEG:PPG = 60:30:10 to 90:10:0 by weight). This composite structure allows the implant to maintain controlled degradation while reducing the harmful acidic byproducts through the buffering effect of the glycol components, thereby preventing tissue necrosis while maintaining acceptable absorption rates.
Solution Approach 2:
The patent modifies the chemical composition parameters of the polymer by controlling the molecular weight and ratio of different components. Specifically, it uses polylactic acid with molecular weight of 10,000 to 1,000,000 and controls the glycol content to be 10-40% by weight. These parameter changes optimize the degradation rate and byproduct generation to prevent tissue necrosis while maintaining structural integrity.
2Productivity
If implants are made to absorb quickly, then degradation rate is improved, but macroscopic fracturing occurs
Solution Approach 1:
The composite structure with polyethylene glycol and polypropylene glycol acts as a reinforcement matrix that prevents macroscopic fracturing during rapid degradation. The glycol components form a continuous phase that maintains structural coherence while the polylactic acid degrades, allowing quick absorption without loss of structural integrity.
Solution Approach 2:
The patent creates local quality differences within the polymer matrix by having different components degrade at different rates. The polylactic acid degrades rapidly while the glycol components provide sustained structural support. This local differentiation of degradation characteristics allows the implant to maintain overall integrity while achieving rapid absorption of the degradable portion.
3Strength
If hydrophobic regions are present in the implant, then mechanical strength is improved, but fibrogenic response increases
Solution Approach 1:
The patent uses a composite system where hydrophilic glycol regions are distributed throughout the hydrophobic polylactic acid matrix. This creates a dual-phase structure where the hydrophilic regions act as stress concentrators that prevent crack propagation and reduce fibrogenic response, while the hydrophobic regions provide mechanical strength. The specific ratio control ensures optimal balance between these competing requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The copolymer ensures controlled degradation, maintaining the structural integrity of the implant while preventing tissue adhesions and fibrosis, thus enhancing the effectiveness of anti-adhesion barriers and promoting normal tissue healing.
Implementation Method 1
biodegradable polylactic acid and polyethylene glycol linked via urethane or urea groups, which maintains planar integrity during degradation
Implementation Method 2
polyethylene glycol... which maintains planar integrity during degradation, reduces pH changes, and minimizes the formation of macroscopic fracturing
Data Source
Figure 1~2
AI summary
The present disclosure provides copolymers useful in medical devices. For example, the disclosure provides copolymers comprising the polymerization product ester block, ether blocks and diisocyanates. In certain embodiments, the disclosure provides a medical copolymer for implantation comprising ester blocks and ether blocks, wherein: the ester blocks comprise a negative free energy transfer and the ether blocks comprise a positive free energy transfer, the ether and ester blocks are less than 1/10 the length of said copolymer, and, the blocks are distributed such that no domain of contiguous blocks possessing the same polarity of free energy transfer are less than 1/3 of the molecular weight of the copolymer. The disclosure further provides methods of making the aforementioned polymers, and medical devices comprising the polymers.